SEI Investments’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$198K Buy
42,376
+17,242
+69% +$59K ﹤0.01% 3044
2026
Q1
$66.1K Buy
+25,134
New +$59.2K ﹤0.01% 3149
2025
Q2
Sell
-12,429
Closed -$19.9K 2806
2025
Q1
$19.9K Buy
12,429
+30
+0.2% +$89 ﹤0.01% 2741
2024
Q4
$44.6K Buy
+12,399
New +$61.7K ﹤0.01% 2676
2023
Q3
Sell
-11,191
Closed -$30.8K 2634
2023
Q2
$30.8K Sell
11,191
-961
-8% -$3.09K ﹤0.01% 2635
2023
Q1
$38.2K Buy
12,152
+917
+8% +$5.4K ﹤0.01% 2643
2022
Q4
$66.3K Sell
11,235
-366
-3% -$3.04K ﹤0.01% 2470
2022
Q3
$102K Buy
+11,601
New +$120K ﹤0.01% 2562

Other funds holding CCCC

SEI Investments's CCCC Position: Q2 2026 in Review

SEI Investments increased its C4 Therapeutics (CCCC) stake by 69% in Q2 2026, buying an estimated $59K and bringing the position to 42,376 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #3044.

SEI Investments first reported a position in CCCC in Q3 2022 and has held it in 8 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • SEI Investments held 42,376 shares of C4 Therapeutics worth $198K as of Q2 2026.
  • SEI Investments bought 17,242 C4 Therapeutics shares in Q2 2026, an estimated $59K.
  • C4 Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #3044 holding.
  • SEI Investments first reported a position in C4 Therapeutics in Q3 2022 and has held it in 8 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.